sodium-morrhuate and Facial-Neoplasms

The effect of Pinyangmycin, Dexamethasonum and Sodium Morrhuate injected concomitantly to treat cavernous hemangioma in oral and maxillofacial regions was evaluated.. The medical records of 350 patients with cavernous hemangioma in oral and maxillofacial regions between January 1998 and January 2002 were reviewed. One hundred and sixty-five of the patients were men, and 185 were women, the sex ratio was 1:1.12. The patients' ages were between 4 months and 55 years. Two hundred and Twenty-six hemangiomas were located in the maxillofacial regions, and 124 located in the oral cavity. The size of the lesions varied from 1 cm x 1 cm to 6 cm x 9 cm. Pinyangmycin, Dexamethasonum and Sodium Morrhuate were injected simultaneously into the lesions or in the vicinity of the cavernous hemangiomas, and the injection might be repeated every 5 to 7 days when necessary, and this process could be repeated 3 to 5 times.. Three hundred and fifty patients were followed up for 6-48 months. The cure and essentially cured rates were 95.48%, the total efficiency rate was 100%.. This method was a safe, simple and effective therapy to manage cavernous hemangioma in the oral and maxillofacial regions.

Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dexamethasone; Facial Neoplasms; Female; Hemangioma, Cavernous; Humans; Infant; Injections; Male; Maxillary Neoplasms; Middle Aged; Mouth Neoplasms; Sodium Morrhuate

To evaluate the effects of Pinyangmycin, Dexamethasonum and Sodium morrhuate injected homochronouly on treatment of cavernous hemangioma in maxillofacial regions.. The medical records of 115 patients with cavernous hemangioma in maxillofacial regions between September, 1996 and September, 1998 were reviewed. Fifty of the patients were men, and 65 were women, with a ratio of 1:1.3. The age of the patients was from 4 months old to 45 years old. 73 of the hemangioma bodies were sited in maxillofacial regions, 42 were sited in oral cavity. The sizes of the lesions varied from 1 cm x 1 cm to 5 cm x 8 cm. Treatment procedure: 1. Preparation: 8 mg Pinyangmycin was dissolved in 5 mg/ml Dexamethasonum and in 4 ml of 1% procain which were ready for use; 2. Injection: 1-5 ml (Pinyangmycin 1.6-8.0 mg) of mixed solution was first injected to the hemangioma, then followed by an injection of 0.5-2.0 ml Sodium morrhuate according to local appearance, size of the tumor and patient's age. Generally, the amount of each injection should not be over 8 mg Pinyangmycin. If the tumor did not subside after an injection, another injection might be repeated every 5-7 days, and this process might be repeated 3-5 times. The total dose of Pinyangmycin should not be over 40 mg.. 115 patients were followed up for 6-24 months. 81 of 115 (70.43%) cases were recovered, and 30 (26.09%) cases were basically recovered. 4 (3.48%) cases got improvement. The recovery rate were 96.52%, and the total efficiency was 100%.. This method may be a safe, simple and effective therapy to cavernous hemangioma in maxillofacial regions.

Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dexamethasone; Facial Neoplasms; Female; Follow-Up Studies; Hemangioma, Cavernous; Humans; Infant; Injections, Intralesional; Jaw Neoplasms; Male; Middle Aged; Orbital Neoplasms; Sodium Morrhuate

Topics: Angiography, Digital Subtraction; Arteriovenous Malformations; Embolization, Therapeutic; Facial Neoplasms; Hemangioma; Humans; Maxillary Neoplasms; Sodium Morrhuate